Angiogénese
Os inibidores da angiogênese são compostos que interferem na formação de novos vasos sanguíneos, um processo crítico no crescimento e metástase do câncer. Ao inibir a angiogênese, esses compostos podem restringir o suprimento de sangue para os tumores, retardando ou interrompendo seu crescimento. Os inibidores da angiogênese são essenciais na pesquisa do câncer e no desenvolvimento terapêutico, fornecendo insights sobre os mecanismos de progressão tumoral e oferecendo potenciais tratamentos para o câncer e outras doenças relacionadas à angiogênese. Na CymitQuimica, oferecemos uma ampla gama de inibidores da angiogênese de alta qualidade para apoiar sua pesquisa em oncologia e biologia vascular.
Subcategorias de "Angiogénese"
- BTK(154 produtos)
- Bcr-Abl(111 produtos)
- EGFR(591 produtos)
- FAK(71 produtos)
- FLT(87 produtos)
- Receptor do Factor de Crescimento Fibroblasto (FGFR)(173 produtos)
- JAK(245 produtos)
- PDGFR(126 produtos)
- RAAS(89 produtos)
- Src(81 produtos)
- Syk(37 produtos)
- Trombina(52 produtos)
- VDA(2 produtos)
- VEGFR(253 produtos)
Exibir 6 mais subcategorias
Foram encontrados 1884 produtos de "Angiogénese"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Tyrphostin AG 112
CAS:Produto Controlado<p>Applications Tyrphostin AG 112 is an EGFR inhibitor.<br></p>Fórmula:C13H8N4OCor e Forma:NeatPeso molecular:236.23Des-(4-(dimethylamino)-2-butenoyl)-Neratinib
CAS:Produto Controlado<p>Applications 6-Amino-4-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-7-ethoxyquinoline-3-carbonitrile, is used in the synthetic preparation of aminopropanamides which is used in irreversible inhibition of epidermal growth factor receptor (EGFR) for potential use in cancer therapy.<br>References Carmi, C., et al.: J. Med. Chem., 55, 2251 (2012)<br></p>Fórmula:C24H20ClN5O2Cor e Forma:NeatPeso molecular:445.92,3-Naphthalic Anhydride
CAS:Produto Controlado<p>Stability Moisture Sensitive<br>Applications 2,3-Naphthalic anhydride is used as a reagent to synthesize analogues of Thalidomide (T338850), an inhibitor of tumour necrosis factor that was once abandoned because it caused birth defects, but is currently used as an inhibitor of angiogenesis in patients with multiple myeloma.<br>References D’Amato, R., et al.: Proc. Nat. Acad. Sci., 91, 4082 (1994); Ehrenpreis, E., et al.: Gastroenterology, 117, 1271 (1999); Parma, T., et al.: Nat. Med., 5, 582 (1999); Singhal, S., et al.: New Engl. J. Med., 341, 1565 (1999)<br></p>Fórmula:C12H6O3Cor e Forma:NeatPeso molecular:198.17Dehydrodivanillin (~90%, contains up to 10% unknown inorganics)
CAS:Fórmula:C16H14O6Cor e Forma:NeatPeso molecular:302.2794-Fmoc-3(R)-morpholinecarboxylic Acid
CAS:Produto Controlado<p>Applications 4-Fmoc-3(R)-morpholinecarboxylic Acid is used to prepare 125I-labeled morpholine-containing RGD ligand of αvβ3 integrin as angiogenesis imaging probe.<br>References Bianchini, F., et al.: J. Med. Chem., 55, 5024 (2012)<br></p>Fórmula:C20H19NO5Cor e Forma:NeatPeso molecular:353.37Tyrphostin AG 1478
CAS:Produto Controlado<p>Applications Tyrphostin AG 1478 is a potent and selective inhibitor of EGFR.<br></p>Fórmula:C16H14ClN3O2Cor e Forma:NeatPeso molecular:315.75Pulsatilla Saponin D (90%)
CAS:Produto Controlado<p>Applications Pulsatilla Saponin D shows antiangiogenic and antitumor activity.<br>References Sang-Won, H. et al.: Carcinogen., 34, 2156 (2013);<br></p>Fórmula:C47H76O17Pureza:90%Cor e Forma:NeatPeso molecular:913.1N-(4-Fluoro-2-methoxy-5-nitrophenyl)-4-(1-methyl-1H-indol-3-yl)-2-pyrimidinamine
CAS:Produto ControladoFórmula:C20H16FN5O3Cor e Forma:Light Yellow To YellowPeso molecular:393.37Atrasentan
CAS:Produto Controlado<p>Applications Atrasentan is a selective antagonist of the endothelin-A (ETA) receptor and binds selectively to the ETA receptor, which may result in inhibition of endothelin-induced angiogenesis and tumor cell proliferation.<br>References Bax, W., et al.: Trends Pharmacol. Sci., 15, 379 (1994); Winn, M., et al.: J. Med. Chem., 39, 1039 (1996); Wu-Wong, J., et al.: J. Pharmacol. Exp. Ther., 281, 791 (1997);<br></p>Fórmula:C29H38N2O6Cor e Forma:Off-WhitePeso molecular:510.62E3330
CAS:E3330 is a potent and selective APE1(Ref-1) inhibitor, which suppressed NF-kappa B DNA-binding activity.Fórmula:C21H30O6Pureza:99.52%Cor e Forma:SolidPeso molecular:378.46SU11274
CAS:SU11274 (Met Kinase Inhibitor)(IC50=10 nM) is a specific Met inhibitor. It shows no significant effects on PGDFRβ, EGFR or Tie2.Fórmula:C28H30ClN5O4SPureza:98.62% - 99.53%Cor e Forma:Orange PowderPeso molecular:568.09Bucillamine
CAS:Bucillamine (DE019) protects against Ischemia/reperfusion injury in high-risk organ transplants and inhibits the production of VEGF.Fórmula:C7H13NO3S2Pureza:99.47%Cor e Forma:SolidPeso molecular:223.31CP-547632
CAS:CP-547632 is an oral ATP-competitive inhibitor of VEGFR-2/FGF kinase with IC50s of 11/9 nM, highly selective, has antitumor activity.Fórmula:C20H24BrF2N5O3SPureza:99.14%Cor e Forma:SolidPeso molecular:532.4Icotinib Hydrochloride
CAS:Icotinib Hydrochloride, an oral EGFR inhibitor (BPI-2009H), may halt cancer growth by blocking EGFR signaling.Fórmula:C22H22ClN3O4Pureza:99.89%Cor e Forma:SolidPeso molecular:427.88PD 173955-Analog1
CAS:PD 173955-Analog1 is a potent c-Src inhibitor known to have activity against a variety of cancers including colon, lung, head and neck carcinoma.Fórmula:C21H14Cl2N4O3Cor e Forma:SolidPeso molecular:441.27VEGFR-2-IN-24
CAS:VEGFR-2-IN-24 is a potent inhibitor of VEGFR-2 (IC50: 0.22 μM) and can be used to study tumors.Fórmula:C28H23N3O6SCor e Forma:SolidPeso molecular:529.56FGFR4-IN-11
CAS:FGFR4-IN-11: selective, covalent FGFR4 inhibitor; IC50=2.1 nM; blocks FGF19 pathway; anticancer.Fórmula:C29H29N5O5Cor e Forma:SolidPeso molecular:527.57c-Met-IN-14
CAS:c-Met-IN-14: selective c-Met kinase inhibitor, IC50 2.89 nM, anticancer, stops G2/M phase, induces A549 cell apoptosis.Fórmula:C34H38ClFN4O7SCor e Forma:SolidPeso molecular:701.2CHMFL-ABL/KIT-155
CAS:CHMFL-ABL/KIT-155 is a highly potent and orally active type II ABL/c-KIT dual kinase inhibitor (IC50s: 46 nM/75 nM).Fórmula:C33H38F3N5O3Pureza:98%Cor e Forma:SolidPeso molecular:609.68EGFR-IN-26
CAS:EGFR-IN-26 is an EGFR inhibitor that can be used in cancer research.Fórmula:C29H34N6O3Cor e Forma:SolidPeso molecular:514.62TRK/ALK-IN-1
TRK/ALK-IN-1: Potent dual TRK & ALK inhibitor; IC50s: 2.2nM (TRKA), 9.3nM (ALK WT), 38nM (ALK L1196M); cancer research potential.Fórmula:C31H35ClF2N8O2SCor e Forma:SolidPeso molecular:657.18FGFR3-IN-1
CAS:FGFR3-IN-1 (compound 1) is a fibroblast growth factor receptor (FGFR) inhibitor that inhibits FGFR1 (IC50: 40 nM), FGFR2 (IC50: 5.1 nM) and FGFR3 (IC50: 12 nM).Fórmula:C28H39N9O3SCor e Forma:SolidPeso molecular:581.73EGFR-IN-51
CAS:<p>EGFR-IN-51 effectively inhibits EGFR and mutations with IC50s of 0.493-461.63 μM; it induces apoptosis in cancer cells.</p>Fórmula:C21H15N3O2SCor e Forma:SolidPeso molecular:373.43AG1433
CAS:AG1433: inhibits tyrosine kinases, PEP carboxylase, PDGFR-β, Flk-1, and angiogenesis.Fórmula:C16H15ClN2O2Cor e Forma:SolidPeso molecular:302.76EGFR-IN-49
CAS:EGFR-IN-49 selectively inhibits EGFR mutations T790M (IC50: 65 nM) & T790M/L858R (IC50: 13.6 nM), triggering apoptosis dose-dependently.Fórmula:C22H15N5O2SCor e Forma:SolidPeso molecular:413.45TIE-2/VEGFR-2 kinase-IN-1
CAS:<p>TIE-2/VEGFR-2 kinase-IN-1 synthesizes inhibitors for angiogenesis-related disease research.</p>Fórmula:C13H11N3O2Cor e Forma:SolidPeso molecular:241.25Erbstatin
CAS:Erbstatin is a tyrosine-protein kinase inhibitor. When combined with foroxymithine, it has antineoplastic activity against L-1210 leukemia.Fórmula:C9H9NO3Cor e Forma:SolidPeso molecular:179.17PD-173956
CAS:<p>PD-173956 is an inhibitor of the Src family tyrosine kinases.</p>Fórmula:C20H13Cl2FN4OCor e Forma:SolidPeso molecular:415.25EGFR-IN-55
CAS:"EGFR-IN-55 targets EGFRWT (70 nM IC50) & EGFRL858R/T790M (3.9 nM IC50), halts NCI-H1975 cell cycle in G0/G1, showing anticancer properties."Fórmula:C25H25Cl2N7O2Cor e Forma:SolidPeso molecular:526.42CP-690550A
CAS:Cp-690550a is a novel JAK3 inhibitor, which is used to treat rheumatoid arthritis, graft rejection, psoriasis, and other immune-mediated diseases.Fórmula:C15H21N5O2Cor e Forma:SolidPeso molecular:303.36EP009
CAS:EP009, a novel, selective, and orally active inhibitor of JAK3, induces therapeutic response in T-cell malignancies.Fórmula:C14H24O2Cor e Forma:SolidPeso molecular:224.34FIIN-4
CAS:FIIN-4 is a covalent inhibitor of FGFR and can be used in studies about metastatic breast cancer.Fórmula:C35H38N8O4Pureza:99.99%Cor e Forma:SolidPeso molecular:634.73WY-135
CAS:WY-135 is a dual inhibitor of ALK and ROS1 (IC50 of 1.4 nM and 1.1 nM, respectively).Fórmula:C28H34ClN9O3SPureza:98%Cor e Forma:SolidPeso molecular:612.15Nazartinib mesylate
CAS:Nazartinib mesylate is a novel, covalent mutant-selective inhibitor of EGFR (Ki and Kinact: 31 nM and 0.222/min on EGFR(L858R/790M) mutant).Fórmula:C27H35ClN6O5SPureza:98%Cor e Forma:SolidPeso molecular:591.12MDK5466
CAS:MDK5466 is an Flt3 inhibitor that acts by preventing glutamate-induced cell death.Fórmula:C21H23N3OSPureza:98%Cor e Forma:SolidPeso molecular:365.49HIV-IN-6
CAS:HIV-IN-6, an anti-HIV agent, blocks replication by targeting SFKs like Hck involved with Nef protein.Fórmula:C20H16N4O3SPureza:97.78%Cor e Forma:SolidPeso molecular:392.43Lavendustin C6
CAS:Lavendustin C6 is a effective tyrosine kinase inhibitor.Fórmula:C20H25NO5Cor e Forma:SolidPeso molecular:359.42FLT3/ITD-IN-3
CAS:<p>FLT3/ITD-IN-3 (Compound 19) is a potent FLT3-ITD inhibitor with IC50 values: FLT3D835Y (0.3 nM), FLT3 (0.4 nM), inhibits AML cell proliferation.</p>Fórmula:C22H26ClN7O2Cor e Forma:SolidPeso molecular:455.94TRK II-IN-1
CAS:<p>TRK II-IN-1: potent type II TRK inhibitor; IC50s: TRKA (3.3 nM), TRKB (6.4 nM), TRKC (4.3 nM), TRKA G667C (9.4 nM); also targets FLT3, RET, VEGFR2.</p>Fórmula:C29H31F3N8OPureza:98%Cor e Forma:SolidPeso molecular:564.6CP-547632 hydrochloride
CAS:CP-547632 hydrochloride: oral VEGFR-2/FGF inhibitor (IC50: 11/9 nM), well-tolerated, antitumor.Fórmula:C20H25BrClF2N5O3SCor e Forma:SolidPeso molecular:568.86VEGFR-2-IN-27
CAS:VEGFR-2-IN-27 (compound 7a) is a potent inhibitor of VEGFR-2 (IC50: 14.8 nM) and can be used in anticancer studies.Fórmula:C25H21FN4O4Cor e Forma:SolidPeso molecular:460.46EGFR-IN-88
CAS:<p>EGFR-IN-88 (Compound 4i), an EGFR inhibitor with an IC50 of 87 nM, exhibits cytotoxic effects on A549 cells at an IC50 of 3.902 μM and can induce cell apoptosis</p>Fórmula:C22H18Cl2N4O2SPureza:98%Cor e Forma:SolidPeso molecular:473.37BAY 2476568
CAS:BAY 2476568 is a selective and potent EGFR inhibitor that acts on both wild-type EGFR (IC50 <0.2 nM) and mutant EGFR (IC50 <0.2 nM).Fórmula:C24H27FN4O4Cor e Forma:SolidPeso molecular:454.49FGFR4-IN-5
CAS:FGFR4-IN-5: potent, selective FGFR4 inhibitor, IC50 6.5 nM, strong in vivo anti-tumor effect, for liver cancer research.Fórmula:C23H23Cl2N5O5Cor e Forma:SolidPeso molecular:520.37DPPY
CAS:DPPY inhibits EGFR, BTK, JAK3 (IC50<10 nM), curbs B-cell lymphoma growth, and may be studied for IPF treatment.Fórmula:C25H26ClN7O3Cor e Forma:SolidPeso molecular:507.97PDGFRα/FLT3-ITD-IN-1
CAS:PDGFRα/FLT3-ITD-IN-1 are potent inhibitors of PDGFRα/FLT3, and their IC50 values are greater than 0.036 and 0.003 μM, respectively.Fórmula:C27H39N9OCor e Forma:SolidPeso molecular:505.66Sitravatinib malate
CAS:<p>Sitravatinib malate is an orally bioavailable receptor inhibitor of tyrosine kinase (RTK) (IC50s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5</p>Fórmula:C37H35F2N5O9SPureza:98%Cor e Forma:SolidPeso molecular:763.76KRC-108
CAS:KRC-108 is a potent kinase inhibitor targeting Ron, Flt3, TrkA, and c-Met with strong anti-proliferative effects on various cancer cells.Fórmula:C20H20N6OCor e Forma:SolidPeso molecular:360.41YF-452
CAS:<p>YF-452 inhibits tumor growth through antiangiogenesis by suppressing VEGF receptor 2 signaling.</p>Fórmula:C24H26BrN3OPureza:98%Cor e Forma:SolidPeso molecular:452.39Multi-kinase-IN-3
CAS:Multi-kinase-IN-3 (compound 2) is a potent inhibitor of angiokinase and inhibits VEGFR-2 (IC50: 58.3 nM) and PDGFRβ (IC50: 55 nM).Fórmula:C33H33N5O3Cor e Forma:SolidPeso molecular:547.65
